Haleos Labs Limited has announced a postal ballot process to seek shareholder approval for a material related party transaction, with the cut-off date scheduled for March 27, 2026. The company will conduct the voting process exclusively through electronic means.

Resolution Details

The postal ballot will address a single ordinary resolution requiring shareholder consent. The resolution seeks approval for a material related party transaction involving the issuance of a corporate guarantee in favour of RBL Bank. This guarantee will secure the external corporate borrowings facility availed by Mahi Drugs Private Limited, which is a subsidiary of Haleos Labs Limited.

Appointed Agencies and Officials

The Board of Directors has made key appointments to facilitate the postal ballot process. Central Depository Services (India) Ltd. has been appointed as the authorized agency to provide the platform for remote e-voting facility to all members. Additionally, Mr. C. Sudhir Babu, a practicing company secretary with FCS No.7666, has been designated as the scrutinizer to conduct the postal ballot and e-voting process in a fair and transparent manner.

Postal Ballot Timeline

The company has established a comprehensive timeline for the postal ballot process. Members whose names appear in the Register of Members or List of Beneficial Owners as on Friday, March 27, 2026, being the cut-off date, will be entitled to vote through the postal ballot.

Regulatory Compliance

The postal ballot process is being conducted in accordance with Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. This announcement follows the company's earlier communication dated February 11, 2026, when the Board of Directors initially decided to seek member consent through the postal ballot process. The company has ensured compliance with all regulatory requirements for conducting the postal ballot exclusively through electronic voting means.

Haleos Labs Limited has announced the reopening of a special window for shareholders to re-lodge physical share transfer requests that were previously rejected or not processed due to documentation deficiencies.

Special Window Details

The company has informed stock exchanges that a special window will remain open for one year, from February 5, 2026 to February 4, 2027. This facility is specifically designed for transfer deeds that were lodged prior to the April 1, 2019 deadline but were either rejected, returned, or not processed due to deficiencies in documentation or other procedural lapses.

Regulatory Framework

The initiative follows SEBI circular no. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The company's announcement, signed by Company Secretary Trupti Ranjan Mohanty, was communicated to both BSE Limited and National Stock Exchange of India Limited on February 28, 2026.

Shareholder Benefits

Shareholders who missed the earlier deadline of January 6, 2026 are encouraged to utilize this opportunity by furnishing necessary documents to the company or its Registrar and Share Transfer Agent, M/s. Purva Sharegistry (India) Private Limited. The company emphasizes that all such transfers will be processed exclusively in demat mode and will be subject to a one-year lock-in period from the date of dematerialization.

Dividend Reminder

The company has also reminded shareholders to claim their unclaimed dividends at the earliest. If dividends remain unclaimed for seven years, both the dividend amount and corresponding shares will be transferred to the Investor Education & Protection Fund Authority (IEPFA).

Company Information

Haleos Labs Limited, formerly known as SMS Lifesciences India Limited, operates from its registered office at Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad-500 096, Telangana. The company can be contacted at +91-40-6628 888 or through info@haleoslabs.com .